ReviewCancer innovation2025
Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens.
Review in Cancer innovation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predictive Biomarkers of Metronomic Chemotherapy Response in Solid Tumors: Chasing an Elusive Signal.Cancers · 2026Review
- Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with capecitabine in HER2-negative advanced breast cancer: a dose-escalation, phase I study.BMC medicine · 2026Article
- Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens.Cancer innovation · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review examines the future of metronomic chemotherapy (MCT) in the treatment of breast cancer and emphasizes its transformative potential. MCT refers to the continuous administration of a low dose of chemotherapeutic agents. It reduces toxicity, improves the quality of life, and demonstrates antitumor effects through multiple mechanisms. Although used as a stand-alone treatment for breast cancer, MCT has been combined with other therapies in recent years to further enhance its antitumor efficacy through mechanisms such as direct cytotoxicity, anti-angiogenesis, and immunomodulation. The findings of recent studies emphasize the benefits of MCT in combination with immunotherapy, endocrine therapy, and targeted therapies such as anti-human epidermal growth factor receptor 2 and anti-angiogenesis agents. Clinical trials on optimizing MCT regimens are underway. MCT is a promising approach that can revolutionize breast cancer treatment by improving patient outcomes and shifting cancer care toward a chronic disease model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.